Cargando…
A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier
Glioblastoma multiforme (GBM) is the most common and lethal central nervous system tumor. Recently, atovaquone has shown inhibition of signal transducer and activator transcription 3, a promising target for GBM therapy. However, it is currently unable to achieve therapeutic drug concentrations in th...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027483/ https://www.ncbi.nlm.nih.gov/pubmed/29783757 http://dx.doi.org/10.3390/pharmaceutics10020060 |
_version_ | 1783336622371110912 |
---|---|
author | Takabe, Hiroyuki Warnken, Zachary N. Zhang, Yajie Davis, Daniel A. Smyth, Hugh D. C. Kuhn, John G. Weitman, Steve Williams III, Robert O. |
author_facet | Takabe, Hiroyuki Warnken, Zachary N. Zhang, Yajie Davis, Daniel A. Smyth, Hugh D. C. Kuhn, John G. Weitman, Steve Williams III, Robert O. |
author_sort | Takabe, Hiroyuki |
collection | PubMed |
description | Glioblastoma multiforme (GBM) is the most common and lethal central nervous system tumor. Recently, atovaquone has shown inhibition of signal transducer and activator transcription 3, a promising target for GBM therapy. However, it is currently unable to achieve therapeutic drug concentrations in the brain with the currently reported and marketed formulations. The present study sought to explore the efficacy of atovaquone against GBM as well as develop a formulation of atovaquone that would improve oral bioavailability, resulting in higher amounts of drug delivered to the brain. Atovaquone was formulated as an amorphous solid dispersion using an optimized formulation containing a polymer and a spontaneously emulsifying component (SEC) with greatly improved wetting, disintegration, dispersibility, and dissolution properties. Atovaquone demonstrated cytotoxicity against GBM cell lines as well as provided a confirmed target for atovaquone brain concentrations in in vitro cell viability studies. This new formulation approach was then assessed in a proof-of-concept in vivo exposure study. Based on these results, the enhanced amorphous solid dispersion is promising for providing therapeutically effective brain levels of atovaquone for the treatment of GBM. |
format | Online Article Text |
id | pubmed-6027483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60274832018-07-13 A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier Takabe, Hiroyuki Warnken, Zachary N. Zhang, Yajie Davis, Daniel A. Smyth, Hugh D. C. Kuhn, John G. Weitman, Steve Williams III, Robert O. Pharmaceutics Article Glioblastoma multiforme (GBM) is the most common and lethal central nervous system tumor. Recently, atovaquone has shown inhibition of signal transducer and activator transcription 3, a promising target for GBM therapy. However, it is currently unable to achieve therapeutic drug concentrations in the brain with the currently reported and marketed formulations. The present study sought to explore the efficacy of atovaquone against GBM as well as develop a formulation of atovaquone that would improve oral bioavailability, resulting in higher amounts of drug delivered to the brain. Atovaquone was formulated as an amorphous solid dispersion using an optimized formulation containing a polymer and a spontaneously emulsifying component (SEC) with greatly improved wetting, disintegration, dispersibility, and dissolution properties. Atovaquone demonstrated cytotoxicity against GBM cell lines as well as provided a confirmed target for atovaquone brain concentrations in in vitro cell viability studies. This new formulation approach was then assessed in a proof-of-concept in vivo exposure study. Based on these results, the enhanced amorphous solid dispersion is promising for providing therapeutically effective brain levels of atovaquone for the treatment of GBM. MDPI 2018-05-19 /pmc/articles/PMC6027483/ /pubmed/29783757 http://dx.doi.org/10.3390/pharmaceutics10020060 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Takabe, Hiroyuki Warnken, Zachary N. Zhang, Yajie Davis, Daniel A. Smyth, Hugh D. C. Kuhn, John G. Weitman, Steve Williams III, Robert O. A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier |
title | A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier |
title_full | A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier |
title_fullStr | A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier |
title_full_unstemmed | A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier |
title_short | A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier |
title_sort | repurposed drug for brain cancer: enhanced atovaquone amorphous solid dispersion by combining a spontaneously emulsifying component with a polymer carrier |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027483/ https://www.ncbi.nlm.nih.gov/pubmed/29783757 http://dx.doi.org/10.3390/pharmaceutics10020060 |
work_keys_str_mv | AT takabehiroyuki arepurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT warnkenzacharyn arepurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT zhangyajie arepurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT davisdaniela arepurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT smythhughdc arepurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT kuhnjohng arepurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT weitmansteve arepurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT williamsiiiroberto arepurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT takabehiroyuki repurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT warnkenzacharyn repurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT zhangyajie repurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT davisdaniela repurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT smythhughdc repurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT kuhnjohng repurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT weitmansteve repurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier AT williamsiiiroberto repurposeddrugforbraincancerenhancedatovaquoneamorphoussoliddispersionbycombiningaspontaneouslyemulsifyingcomponentwithapolymercarrier |